Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.

Date publication

octobre 2019

Journal

Gynecologic oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr KALBACHER Elsa

Tous les auteurs :
Labidi-Galy SI, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, Combes JD, Heimgartner-Hu K, Tredan O, Guevara H, Heudel PE, Reverdy T, Bazan F, Heinzelmann-Schwarz V, Fehr M, de Castelbajac V, Vaflard P, Crivelli L, Bonadona V, Viassolo V, Buisson A, Golmard L, Rodrigues M, Ray-Coquard I

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31604666

Résumé

To investigate clinical factors associated with prolonged progression-free survival (PFS) and overall survival (OS) in relapsing epithelial ovarian cancer (EOC) patients with BRCA mutations and receiving olaparib as maintenance therapy in daily practice.

Mots clés

BRCA mutation, Maintenance, Olaparib, Ovarian cancer, PARP inhibitor, Prognostic, Survival

Référence

Gynecol. Oncol.. 2019 Oct 8;: